Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright

RenovoRx, Inc. (NASDAQ:RNXT) – Analysts at HC Wainwright lowered their Q2 2025 earnings estimates for shares of RenovoRx in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.08) per share for the quarter, down from their previous forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for RenovoRx’s Q3 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.29) EPS and FY2027 earnings at $0.08 EPS.

Separately, Ascendiant Capital Markets increased their price objective on shares of RenovoRx from $9.00 to $11.00 and gave the company a “buy” rating in a report on Monday, April 28th.

RenovoRx Stock Performance

Shares of RenovoRx stock opened at $1.22 on Wednesday. The firm has a market capitalization of $44.62 million, a PE ratio of -2.14 and a beta of 1.12. RenovoRx has a twelve month low of $0.75 and a twelve month high of $1.69. The firm’s 50-day moving average price is $0.99 and its 200 day moving average price is $1.14.

RenovoRx (NASDAQ:RNXT) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.23 million.

Institutional Trading of RenovoRx

A number of hedge funds and other institutional investors have recently made changes to their positions in RNXT. AIGH Capital Management LLC acquired a new stake in shares of RenovoRx during the 1st quarter worth approximately $3,433,000. AWM Investment Company Inc. acquired a new stake in shares of RenovoRx during the 1st quarter worth approximately $2,262,000. Alyeska Investment Group L.P. acquired a new stake in shares of RenovoRx during the 1st quarter worth approximately $682,000. ADAR1 Capital Management LLC boosted its position in shares of RenovoRx by 143.3% during the 1st quarter. ADAR1 Capital Management LLC now owns 479,883 shares of the company’s stock worth $475,000 after purchasing an additional 282,633 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in shares of RenovoRx during the 1st quarter worth approximately $275,000. Institutional investors and hedge funds own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.